Stay updated on Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.2 to version 2.16.3.
    Difference
    0.1%
    Check dated 2025-06-13T15:59:32.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-06T09:54:23.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    1.0%
    Check dated 2025-05-30T04:46:07.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.0, replacing the previous version 2.15.2.
    Difference
    0.2%
    Check dated 2025-05-23T02:04:09.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-05-01T06:07:04.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version of the study, with significant changes including the removal of detailed study objectives and inclusion criteria for a pilot study on pembrolizumab-based therapy for high-grade neuroendocrine carcinomas, while adding a new diagnosis and registry identifier.
    Difference
    54%
    Check dated 2025-04-16T17:36:57.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.